Abstract:Objectives: The incidence of infections in patients with malignant hematologic diseases is extremely high and significantly affects their prognosis. Identifying early and precise biomarkers for infection is crucial for guiding the treatment of infections in these patients. Previous studies have shown that procalcitonin (PCT) can serve as an early diagnostic marker for bloodstream infections in patients with malignant hematologic diseases. This study aims to compare serum PCT levels in these patients with different pathogens, disease types, infection sites, and severity levels. Methods: Clinical data and laboratory results of infected patients with malignant hematologic diseases treated at the Department of Hematology, the Third Xiangya Hospital of Central South University from January 2018 to August 2023 were collected. General patient information was retrospectively analyzed. Serum PCT levels were compared among patients with different pathogens, types of malignant hematologic diseases, infection sites, and infection severity; Receiver operator characteristic (ROC) curves were used to determine the cut-off values and diagnostic value of serum PCT levels in diagnosing bloodstream infections versus local infections and severe infections versus non-severe infections. Mortality rates after 4-7 days of anti-infective treatment were compared among groups with rising, falling, and unchanged PCT levels. Results: A total of 526 patients with malignant hematologic diseases were included. The main pathogens were Gram-negative bacteria (272 cases, 51.7%), followed by Gram-positive bacteria (120 cases, 22.8%), fungi (65 cases, 12.4%), viruses (23 cases, 4.4%), and mixed pathogens (46 cases, 8.7%). The main types of malignant hematologic diseases were acute myeloid leukemia (216 cases, 41.1%), acute lymphoblastic leukemia (107 cases, 20.3%), and lymphoma (93 cases, 17.7%). Granulocyte deficiency was present in 68.3% (359 cases) of the patients during infection, with severe infection in 24.1% (127 cases). Significant differences in serum PCT levels were found among patients with different types of pathogens (P<0.001), with the highest levels in Gram-negative bacterial infections. Significant differences in serum PCT levels were also found among patients with different types of malignant hematologic diseases (P<0.05), with the highest levels in lymphoma patients. Serum PCT levels were significantly higher in systemic infections and severe infections compared to local infections and non-severe infections (both P<0.001). ROC curve analysis showed that the cut-off values for diagnosing bloodstream infections and severe infections were 0.22 and 0.28 ng/mL, with areas under the curve of 0.670 and 0.673, respectively. After 4-7 days of anti-infective treatment, the mortality rates of the PCT declining, PCT unchanged, and PCT rising groups were 11.9%, 21.2%, and 35.7%, respectively, and pairwise comparisons were statistically significant (all P<0.05). Conclusions: PCT can be used as an auxiliary indicator for early identification of different pathogens, infection sites, and severity levels in patients with malignant hematologic diseases combined with infections. Dynamic monitoring of PCT levels after empirical antibiotic treatment provides important guidance for assessing patient's prognosis.

The Predictive Value of Procalcitonin for Early Detection of Infection in Elderly Type 2 Diabetes Mellitus

Procalcitonin and C-reactive Protein Predict Infection in Hematopoietic Stem Cell Transplantation Patients.

Predictive Value of Cytokines and Procalcitonin on Infection in Children with Hematological Malignancies

Investigation on the value of procalcitonin in diagnosing lower respiratory tract infection in adult

Diagnostic value of procalcitonin in infections in patients with malignant hematologic diseases

Clinical value of procalcitonin test for early diagnosis of sepsis in the emergency department

[Value of Procalcitonin in the Early Diagnosis of Sepsis in Department of Emergency].

Prognostic Value of Procalcitonin in Adult Patients with Sepsis: A Systematic Review and Meta-Analysis

The Diagnostic Ability of Procalcitonin to Differentiate Gram-negative Bacteria from Gram-positive Bacteria and Fungal Bloodstream Infections in Critically Ill Patients

Evaluation of Diagnostic and Prognostic Value of Procalcitonin in Critical Ill Patients with Sepsis

Multicenter prospective study of procalcitonin as an indicator of sepsis

The utility of initial procalcitonin and procalcitonin clearance for prediction of bacterial infection and outcome in critically ill patients with autoimmune diseases: a prospective observational study

Comparison of the Diagnostic Power Between Cytokine Pattern and Procalcitonin for Predicting Infection in Pediatric Hematology/Oncology Patients

Using procalcitonin levels to predict infection and reduce unnecessary antibiotic usage in febrile children aged 3-36 months

Procalcitonin-guided diagnosis and antibiotic stewardship revisited

Clinical significance of serum procalcitonin in patients with infection after hematopoietic stem cell transplantation

The predicting value of serum procalcitonin in treatment of acute exacerbations of chronic obstructive pulmonary disease in elderly patients

Diagnostic Value and Prognostic Significance of Procalcitonin Combined with C-Reactive Protein in Patients with Bacterial Bloodstream Infection.

Diagnostic value of procalcitonin for bacterial infections in patients undergoing hemodialysis: a systematic review and meta-analysis

B-095 The level of procalcitonin is a biomarker for differentiation between pathogenic and non-pathogenic bacteria

[Value of Serum Procalcitonin and Acute Physiology and Chronic Health Evaluation II Score on Predicting the Prognosis of Sepsis in Elderly Patients].